Aktuellt
SENASTE
Redeye is encouraged by yet another record quarter by BONESUPPORT, but we have made some considerable reconsiderations to our initial take on our financial forecasts, rendering some minor changes to our fair value range. For the remainder of the year, we expect an exciting news flow, with the single-most-important catalyst being a potential FDA approval, which could come any day now.
LÄS MER
